Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns “Buy” Rating from HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average price target of $5.00.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock traded down $0.35 during trading hours on Monday, hitting $0.35. 44,168,289 shares of the company’s stock were exchanged, compared to its average volume of 5,609,503. Lexicon Pharmaceuticals has a 12-month low of $0.35 and a 12-month high of $2.83. The company has a market capitalization of $86.43 million, a PE ratio of -0.47 and a beta of 1.04. The business’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $1.18. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Bayesian Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $31,000. RPO LLC bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth $33,000. Renaissance Technologies LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at $38,000. Arizona State Retirement System grew its position in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas lifted its position in Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 24,615 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.